T. T. Ashburn, T. , and K. B. , Drug repositioning: identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov, vol.3, pp.673-683, 2004.

B. Aslam, W. Wang, M. I. Arshad, M. Khurshid, S. Muzammil et al., Antibiotic resistance: a rundown of a global crisis, Infect. Drug Resist, vol.11, pp.1645-1658, 2018.

R. Ayerbe-algaba, M. L. Gil-marqués, M. E. Jiménez-mejías, V. Sánchez-encinales, R. Parra-millán et al., synergistic activity of niclosamide in combination with colistin against colistin-susceptible and colistin-resistant Acinetobacter baumannii and Klebsiella pneumoniae, Front. Cell. Infect. Microbiol, vol.8, p.348, 2018.

A. Azvolinsky, Repurposing existing drugs for new indications. The Scientist, 2017.

T. Bachiri, S. Bakour, R. Lalaoui, N. Belkebla, M. Allouache et al., Occurrence of Carbapenemase-producing Enterobacteriaceae isolates in the wildlife: first report of OXA-48 in wild boars in Algeria, Microb. Drug Resist, vol.24, pp.337-345, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01780658

M. Bassetti, G. Poulakou, E. Ruppe, E. Bouza, S. J. Van-hal et al., Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach, Intensive Care Med, vol.43, pp.1464-1475, 2017.

S. Biswas, J. M. Brunel, J. C. Dubus, M. Reynaud-gaubert, and J. M. Rolain, Colistin: an update on the antibiotic of the 21st century, Expert Rev. Anti. Infect. Ther, vol.10, pp.917-934, 2012.

A. Cannatelli, S. Principato, O. L. Colavecchio, L. Pallecchi, and G. M. Rossolini, Synergistic activity of colistin in combination with resveratrol against colistin-resistant gram-negative pathogens, Front. Microbiol, vol.9, p.1808, 2018.

K. M. Carlson-banning, A. Chou, Z. Liu, R. J. Hamill, Y. Song et al., Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae, PLoS ONE, vol.8, p.69646, 2013.

N. Cassir, J. M. Rolain, and P. Brouqui, A new strategy to fight antimicrobial resistance: the revival of old antibiotics, Front. Microbiol, vol.5, p.551, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01244650

T. Cebrero-cangueiro, R. Álvarez-marín, G. Labrador-herrera, Y. Smani, E. Cordero-matía et al., In vitro Activity of pentamidine alone and in combination with aminoglycosides, tigecycline, rifampicin, and doripenem against clinical strains of carbapenemase-producing and/or colistin-resistant Enterobacteriaceae, Front. Cell. Infect. Microbiol, vol.8, p.363, 2018.

H. Chen, J. Wu, Y. Gao, H. Chen, and J. Zhou, Scaffold repurposing of old drugs towards new cancer drug discovery, Curr. Top. Med. Chem, vol.16, pp.2107-2114, 2016.

Y. S. Cheng, W. Sun, M. Xu, M. Shen, M. Khraiwesh et al., Repurposing screen identifies unconventional drugs with activity against multidrug resistant Acinetobacter baumannii, Front. Cell. Infect. Microbiol, vol.8, p.438, 2019.

J. Conly and B. Johnston, Where are all the new antibiotics? The new antibiotic paradox. Can, J. Infect. Dis. Med. Microbiol, vol.16, pp.159-160, 2005.

F. D'angelo, V. Baldelli, N. Halliday, P. Pantalone, F. Polticelli et al., Identification of FDA-approved drugs as antivirulence agents targeting the pqs quorum-sensing system of Pseudomonas aeruginosa, Antimicrob. Agents Chemother, vol.24, p.62, 2018.

B. Davido, R. Batista, H. Michelon, M. Lepainteur, F. Bouchand et al., Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage?, J. Hosp. Infect, vol.95, pp.433-437, 2017.

R. Deuil, Treatment for diabetes with sulfamide hypoglycemic agents, Rev. Prat, vol.6, pp.3687-3694, 1956.

S. M. Diene and J. M. Rolain, Investigation of antibiotic resistance in the genomic era of multidrug-resistant gram-negative bacilli, especially Enterobacteriaceae Pseudomonas Acinetobacter, Expert Rev. Anti. Infect. Ther, vol.11, pp.277-296, 2013.

T. L. Doan, M. Pollastri, M. A. Walters, G. , and G. I. , The future of drug repositioning: old drugs, new opportunities, Annu. Rep. Med. Chem, vol.46, pp.385-401, 2011.

M. Doerflinger, W. Forsyth, G. Ebert, M. Pellegrini, H. et al., CRISPR/Cas9-The ultimate weapon to battle infectious diseases?, Cell. Microbiol, vol.19, p.12693, 2017.

A. Doléans-jordheim, E. Bergeron, F. Bereyziat, S. Ben-larbi, O. Dumitrescu et al., Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains, Eur. J. Clin. Microbiol. Infect. Dis, vol.30, pp.1249-1256, 2011.

M. E. Ebada, Drug repurposing may generate novel approaches to treating depression, J. Pharm. Pharmacol, vol.69, pp.1428-1436, 2017.

L. P. Elwell, R. Ferone, G. A. Freeman, J. A. Fyfe, J. A. Hill et al., Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U), Antimicrob. Agents Chemother, vol.31, pp.274-280, 1987.

P. Fernandes and E. Martens, Antibiotics in late clinical development, Biochem. Pharmacol, vol.133, pp.152-163, 2017.

, Available online at, Global Antimicrobial Resistance Surveillance System, GLASS, Report early implementation, 2019.

C. H. Goss, Y. Kaneko, L. Khuu, G. D. Anderson, S. Ravishankar et al., Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections, Sci. Transl. Med, vol.10, p.7520, 2018.

K. Gould, Antibiotics: from prehistory to the present day, J. Antimicrob. Chemother, vol.71, pp.572-575, 2016.

M. M. Hashemi, J. Rovig, S. Weber, B. Hilton, M. M. Forouzan et al., Susceptibility of colistin-resistant, gram-negative bacteria to antimicrobial peptides and ceragenins, Antimicrob. Agents Chemother, vol.25, p.61, 2017.

S. Hijazi, D. Visaggio, M. Pirolo, E. Frangipani, L. Bernstein et al., Antimicrobial activity of gallium compounds on ESKAPE pathogens, Front. Cell. Infect. Microbiol, vol.8, p.316, 2018.

R. A. Hodos, B. A. Kidd, K. Shameer, B. P. Readhead, and J. T. Dudley, silico methods for drug repurposing and pharmacology, vol.8, pp.186-210, 2016.

Y. Hu and P. A. Coates, Combination Comprising Zidovudine and Polymyxin, 2014.

Y. Hu, Y. Liu, and A. Coates, Azidothymidine produces synergistic activity in combination with colistin against antibiotic-resistant Enterobacteriaceae, Antimicrob. Agents Chemother, vol.63, pp.1630-1648, 2018.

M. H. Hussein, E. K. Schneider, A. G. Elliott, M. Han, F. Reyes-ortega et al., From breast cancer to antimicrobial: combating extremely resistant gram-negative "superbugs" using novel combinations of polymyxin B with selective estrogen receptor modulators, Microb. Drug Resist, vol.23, pp.640-650, 2017.

M. Jung, J. Contreras, C. Morice, J. Simon, B. Didier et al., The Prestwick Chemical Library : a valuable tool for screening, 1997.

. Vidal, , 2018.

S. S. Kadri, J. Adjemian, Y. L. Lai, A. B. Spaulding, E. Ricotta et al., Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents, Clin. Infect. Dis, vol.67, pp.1803-1814, 2018.

T. W. Kim, Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease, Neurotherapeutics, vol.12, pp.132-142, 2015.

J. Langedijk, A. K. Mantel-teeuwisse, D. S. Slijkerman, and M. H. Schutjens, Drug repositioning and repurposing: terminology and definitions in literature, Drug Discov. Today, vol.20, pp.1027-1034, 2015.

G. L. Law, J. Tisoncik-go, M. J. Korth, and M. G. Katze, Drug repurposing: a better approach for infectious disease drug discovery?, Curr. Opin. Immunol, vol.25, pp.588-592, 2013.

J. R. Lenhard, R. L. Nation, and B. T. Tsuji, Synergistic combinations of polymyxins, Int. J. Antimicrob. Agents, vol.48, pp.607-613, 2016.

C. S. Lewin, R. Allen, and S. G. Amyes, Zidovudine-resistance in salmonella typhimurium and Escherichia coli, J. Antimicrob. Chemother, vol.25, pp.706-714, 1990.

C. S. Lewin, R. A. Allen, and S. G. Amyes, Antibacterial activity of fluoroquinolones in combination with zidovudine, J. Med. Microbiol, vol.33, pp.127-131, 1990.

M. Loose, K. G. Naber, Y. Hu, A. Coates, and F. M. Wagenlehner, Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli, Int. J. Antimicrob. Agents, vol.52, pp.783-789, 2018.

M. T. Mascellino, E. Iona, F. Iegri, P. Gregoris, and S. Farinelli, In vitro activity of zidovudine alone and in combination with ciprofloxacin against salmonella and Escherichia coli, FEMS Immunol. Med. Microbiol, vol.7, pp.23-28, 1993.

B. Mercorelli, G. Pal, and A. Loregian, Drug repurposing for viral infectious diseases: how far are we?, Trends Microbiol, 2018.

A. Miró-canturri, R. Ayerbe-algaba, and Y. Smani, Drug repurposing for the treatment of bacterial and fungal infections, Front. Microbiol, vol.10, p.41, 2019.

K. I. Mohr, History of antibiotics research, Curr. Top. Microbiol. Immunol, vol.398, pp.237-272, 2016.

M. Monaco, T. Giani, M. Raffone, F. Arena, A. Garcia-fernandez et al., Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, Euro Surveill, vol.19, 2013.

S. M. Ng, J. S. Sioson, J. M. Yap, F. M. Ng, H. S. Ching et al., Repurposing zidovudine in combination with tigecycline for treating carbapenem-resistant Enterobacteriaceae infections, Eur. J. Clin. Microbiol. Infect. Dis, vol.37, pp.141-148, 2018.

L. Okdah, S. Le-page, A. O. Olaitan, G. Dubourg, L. Hadjadj et al., New therapy from old drugs: synergistic bactericidal activity of sulfadiazine with colistin against colistin-resistant bacteria, including plasmidmediated colistin-resistant mcr-1 isolates, Int. J. Antimicrob. Agents, vol.51, pp.775-783, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01801665

A. O. Olaitan, S. M. Diene, M. Kempf, M. Berrazeg, S. Bakour et al., Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Int. J. Antimicrob. Agents, vol.44, pp.500-507, 2014.

R. G. Otto, E. Van-gorp, W. Kloezen, J. Meletiadis, . Van-den et al., An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics, Int. J. Antimicrob. Agents, vol.53, pp.34-39, 2019.

K. M. Parmar, Z. J. Hathi, and N. A. Dafale, Control of multidrugresistant gene flow in the environment through bacteriophage intervention, 2017.

, Appl. Biochem. Biotechnol, vol.181, pp.1007-1029

L. Peyclit, S. A. Baron, H. Yousfi, and J. M. Rolain, Zidovudine: a salvage therapy for mcr-1 plasmid-mediated colistin-resistant bacterial infections?, Int. J. Antimicrob. Agents, vol.52, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01858892

A. Rangel-vega, L. R. Bernstein, E. A. Mandujano-tinoco, S. J. García-contreras, and R. García-contreras, Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections, Front. Microbiol, vol.6, p.282, 2015.

I. Roca, M. Akova, F. Baquero, J. Carlet, M. Cavaleri et al., The global threat of antimicrobial resistance: science for intervention, New Microbes New Infect, vol.6, pp.22-29, 2015.

J. Rolain, Food and human gut as reservoirs of transferable antibiotic resistance encoding genes, Front. Microbiol, vol.4, p.173, 2013.

J. M. Rolain and F. Baquero, The refusal of the society to accept antibiotic toxicity: missing opportunities for therapy of severe infections, Clin. Microbiol. Infect, vol.22, pp.423-427, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01458380

E. K. Schneider, F. Reyes-ortega, T. Velkov, L. , and J. , Antibiotic-nonantibiotic combinations for combating extremely drug-resistant gram-negative 'superbugs, Essays Biochem, vol.61, pp.115-125, 2017.

J. A. Seukep, L. P. Sandjo, B. T. Ngadjui, and V. Kuete, Antibacterial and antibiotic-resistance modifying activity of the extracts and compounds from Nauclea pobeguinii against gram-negative multi-drug resistant phenotypes, BMC Complement. Altern. Med, vol.16, p.193, 2016.

L. Sleire, H. E. Førde, I. A. Netland, L. Leiss, B. S. Skeie et al., Drug repurposing in cancer, Pharmacol. Res, vol.124, pp.74-91, 2017.

V. Soo, B. Kwan, H. Quezada, I. Castillo-juárez, B. Pérez-eretza et al., Repurposing of anticancer drugs for the treatment of bacterial infections, Curr. Top. Med. Chem, vol.17, pp.1157-1176, 2017.

B. Spellberg, J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards, Trends in Antimicrobial drug development: implications for the future, Clin. Infect. Dis, vol.38, pp.1279-1286, 2004.

J. M. Stokes, C. R. Macnair, B. Ilyas, S. French, J. P. Côté et al., Pentamidine sensitizes gram-negative pathogens to antibiotics and overcomes acquired colistin resistance, Nat. Microbiol, vol.2, p.17028, 2017.

J. Sun, J. Yang, J. Chi, X. Ding, and N. Lv, Identification of drug repurposing candidates based on a miRNA-mediated drug and pathway network for cardiac hypertrophy and acute myocardial infarction, Hum. Genomics, vol.12, p.52, 2018.

W. Sun, P. E. Sanderson, and W. Zheng, Drug combination therapy increases successful drug repositioning, Drug Discov. Today, vol.21, pp.1189-1195, 2016.

W. Sun, R. A. Weingarten, M. Xu, N. Southall, S. Dai et al., Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria, Emerg. Microbes Infect, vol.9, p.5, 2016.

R. Tafoukt, T. Leangapichart, L. Hadjadj, S. Bakour, S. M. Diene et al., Characterization of bla OXA-538, a new variant of bla OXA-48 in shewanella xiamenensis isolated from river water in Algeria, J. Glob. Antimicrob. Resist, 2017.

L. Terra, P. J. Dyson, M. D. Hitchings, L. Thomas, A. Abdelhameed et al., A novel alkaliphilic streptomyces inhibits ESKAPE pathogens, Front. Microbiol, vol.9, p.2458, 2018.

N. S. Torres, J. J. Abercrombie, A. Srinivasan, J. L. Lopez-ribot, A. K. Ramasubramanian et al., Screening a commercial library of pharmacologically active small molecules against Staphylococcus aureus biofilms, Antimicrob. Agents Chemother, vol.60, pp.5663-5672, 2016.

T. B. Tran, J. Wang, Y. Doi, T. Velkov, P. J. Bergen et al., Novel Polymyxin Combination with antineoplastic mitotane improved the bacterial killing against polymyxin-resistant multidrug-resistant gram-negative pathogens, Front. Microbiol, vol.9, p.721, 2018.

Y. M. Wang, L. C. Kong, J. Liu, and H. X. Ma, Synergistic effect of eugenol with Colistin against clinical isolated colistin-resistant Escherichia coli strains, Antimicrob. Resist. Infect. Control, vol.7, p.17, 2018.

, Les 10 principales causes de mortalité (Top 10 causes of death), 2018.

Y. Yang and K. L. Chua, Assessment of the effect of efflux pump inhibitors on in vitro antimicrobial susceptibility of multidrugresistant Acinetobacter baumannii, Int. J. Antimicrob. Agents, vol.42, pp.283-284, 2013.

K. Zenati, A. Touati, S. Bakour, F. Sahli, and J. M. Rolain, Characterization of NDM-1-and OXA-23-producing Acinetobacter baumannii isolates from inanimate surfaces in a hospital environment in Algeria, J. Hosp. Infect, vol.92, pp.19-26, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01459925

W. Zheng, W. Sun, and A. Simeonov, Drug repurposing screens and synergistic drug-combinations for infectious diseases, Br. J. Pharmacol, vol.175, pp.181-191, 2018.

Y. Zhou, S. Liu, T. Wang, H. Li, S. Tang et al., Pterostilbene, a potential MCR-1 inhibitor that enhances the efficacy of polymyxin B, Antimicrob. Agents Chemother, vol.27, p.62, 2018.